Alcidion Group Ltd (ASX: ALC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $134.98 million
P/E Ratio 58.82
Dividend Yield 0.00%
Shares Outstanding 1.35 billion
Earnings per share 0.002
Dividend per share N/A
Year To Date Return -4.76%
Earnings Yield 1.70%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Alcidion Group Ltd (ASX: ALC)
    Latest News

    A man in his 30s holds his laptop and operates it with his other hand as he has a look of pleasant surprise on his face as though he is learning something new or finding hidden value in something on the screen.
    Earnings Results

    Alcidion share price charges 9% ahead on record quarter

    The company's share price has suffered throughout 2023, but the business fundamentals of Alcidion are moving in the right direction.

    Read more »

    Two kids in superhero capes.
    Small Cap Shares

    'Upside surprise': 2 small-cap ASX shares ready to break out

    The seas are rough, but Cyan's Dean Fergie reminds investors you need to hold on tight if you still believe…

    Read more »

    A cool young man walking in a laneway holding a takeaway coffee in one hand and his phone in the other reacts with surprise as he reads the latest news on his mobile phone
    Broker Notes

    Leading brokers name 3 ASX shares to buy today

    Analysts believe that now could be the time to add these shares to your portfolio...

    Read more »

    two children squat down in the dirt with gardening tools and a watering can wearing denim overalls and smiling very sweetly.
    Growth Shares

    ASX shares: Invest in these 2 stocks for a legit chance at $1 million

    The key to achieving a $1 million portfolio is finding big compounding potential in small places...

    Read more »

    A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
    ASX Share Market News

    3 ASX All Ordinaries shares getting hammered on quarterly updates

    Monday has not been kind to these ASX All Ords shares...

    Read more »

    Two men looking at laptop and cheering.
    Opinions

    Skin in the game: The ASX share in my portfolio I'm most excited about

    Our Foolish writers spill the tea on the shares they own and have the highest hopes for.

    Read more »

    three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
    Small Cap Shares

    3 battered small-cap ASX shares we're still backing: expert

    Smaller businesses saw their valuations tumble in a troubled year like 2022, but will likely rocket up higher and faster…

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    ASX Share Market News

    Top fund manager thinks ASX could start to move decisively higher, potentially sooner than you might be expecting

    Two ASX small cap stocks with material upside potential.

    Read more »

    A happy woman holding an umbrella in front of a rainbow.
    Best Shares

    Top ASX shares to buy in September 2022

    These are the stocks our Foolish writers think could be set to blossom in spring.

    Read more »

    a man sits at his computer screen scrolling with his fingers with a satisfied smile on his face as though he is very content with the news he is receiving.
    Earnings Results

    3 ASX All Ords shares lifting on full-year results

    It's been a good day so far for these companies delivering their earnings results on Tuesday.

    Read more »

    A young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
    Share Gainers

    Why Alcidion, Betmakers, BrainChip, and Zip shares are racing higher

    These ASX shares are pushing higher on Wednesday...

    Read more »

    Five healthcare workers standing together and smiling.
    Technology Shares

    Alcidion share price surges 18% higher on record quarter

    Alcidion shares are on fire on Wednesday...

    Read more »

    Frequently Asked Questions

    No, Alcidion does not pay dividends at this time.

    Alcidion listed on the ASX on 24 June 2011.

    ALC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Alcidion Group Ltd

    Alcidion Group Ltd (ASX: ALC) is a provider of intelligent informatics software for the healthcare sector.

    The company builds, sells, delivers, runs, and supports solutions for healthcare providers. These include clinical, analytical, managerial, and administrative systems.

    Its products include its Miya suite, a Fast Healthcare Interoperability Resources (FHIR) system that allows comprehensive healthcare data to be exchanged between different computer systems.  Other products include Smartpage and Patientrack software.

    Alcidion derives the majority of its revenue from its Australia/New Zealand segment and also has a presence in the United Kingdom.

    ALC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    23 Oct 2026 $0.10 $0.00 0.00% 555,875 $0.10 $0.10 $0.10
    22 Oct 2026 $0.10 $0.00 0.00% 760,738 $0.10 $0.10 $0.10
    21 Oct 2026 $0.10 $0.00 0.00% 53,609 $0.10 $0.10 $0.10
    20 Oct 2026 $0.10 $0.00 0.00% 612,050 $0.10 $0.10 $0.09
    19 Oct 2026 $0.10 $0.00 0.00% 1,535,176 $0.10 $0.10 $0.10
    16 Oct 2026 $0.10 $0.00 0.00% 98,168 $0.10 $0.10 $0.10
    15 Oct 2026 $0.10 $0.00 0.00% 288,052 $0.10 $0.10 $0.10
    14 Oct 2026 $0.10 $0.00 0.00% 367,831 $0.10 $0.10 $0.10
    13 Oct 2026 $0.10 $0.00 0.00% 504,982 $0.10 $0.10 $0.10
    12 Oct 2026 $0.10 $0.00 0.00% 795,918 $0.10 $0.10 $0.10
    09 Oct 2026 $0.10 $0.00 0.00% 1,770,034 $0.10 $0.10 $0.10
    08 Oct 2026 $0.10 $0.00 0.00% 1,702,025 $0.11 $0.11 $0.10
    07 Oct 2026 $0.11 $0.00 0.00% 179,483 $0.11 $0.11 $0.10
    06 Oct 2026 $0.10 $0.00 0.00% 1,189,226 $0.10 $0.11 $0.10
    05 Oct 2026 $0.10 $0.00 0.00% 277,548 $0.10 $0.11 $0.10
    02 Oct 2026 $0.10 $0.00 0.00% 317,762 $0.10 $0.11 $0.10
    01 Oct 2026 $0.11 $-0.01 -9.09% 1,961,489 $0.11 $0.11 $0.10
    30 Sep 2026 $0.11 $0.01 9.52% 2,150,057 $0.11 $0.11 $0.10
    29 Sep 2026 $0.11 $0.00 0.00% 29,548 $0.10 $0.11 $0.10
    28 Sep 2026 $0.11 $0.00 0.00% 562,235 $0.11 $0.11 $0.10

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Oct 2026 William (Bill) Smart Buy 200,000 $20,851
    On-market trade.
    26 Aug 2026 Andrew Way Buy 107,526 $9,999
    On-market trade.
    26 Aug 2026 Andrew Way Buy 107,526 $9,999
    On-market trade.
    24 Aug 2026 Andrew Way Buy 107,526 $9,999
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Rebecca Jayne Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
    Ms Wilson is an experienced company director with private, ASX listed and not-for-profit organisations. In her previous career, she held global leadership roles in marketing communication, investor relations, and corporate affairs. She has deep expertise in ESG, complex stakeholder communication, issues, crisis and risk management, transactions, and investor relations. She worked with multinational and growth companies in technology, healthcare, retail, and professional services sectors. Rebecca is experienced in leading companies during important commercial activation phases working with CEOs as both an advisor and non-executive director to develop and execute effective business strategy that supports accelerated and sustained growth. Rebecca is currently the Non-Executive Chair of AI-enabled technology company Clever Culture Systems Limited, and a Non-Executive Director of Hansen Technologies and Vitura Health Limited. She is a Non-Executive Director of NFP, The Tomisich Foundation and Veski. She is the chair of the Board.
    Mr William (Bill) Smart Non-Executive Director Oct 2024
    Mr Smart is a digital health leader with over 30 years of experience leading transformational changes in organizations. Will has a track record of driving politically sensitive and operationally critical initiatives, enhancing organizational performance. Based in the United Kingdom, Will is currently Vice Chair of Aneurin Bevan University Health Board, Chair of the British Computer Society Faculty of Health and Care and was previously the CIO for Health and Social Care for England. In that role, Will provided advice to the Secretary of State for Health and Social Care and developed and delivered national strategies on information, technology and informatics. He has held executive roles in several NHS Trusts including as the Digital NED for Great Western Hospitals NHS FT, Group Chief Information Officer, Royal Free London NHS Foundation Trust. Will previously served as the Global Director of External Relations, Dedalus Group where he had responsibilities across the UK and Europe and led the launch of their European built Electronic Patient Record (EPR) solution into Ireland and the UK.
    Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Ms Quirke has 25+ years of health sector experience and has been involved in procurements and implementations of healthcare information technology across Australia, New Zealand, the United Kingdom and South-East Asia. Her background includes leading management roles at healthcare software firms where she has driven strategic product direction, global sales and operations. She believes technology can enable the transformation of healthcare delivery. Kate is currently a Non-Executive Director of ANDHealth.
    Mr Daniel Sharp Non-Executive Director Sep 2021
    Mr Sharp has over 25 years of senior executive experience in investment banking and corporate finance. He was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Danny headed the corporate finance division at two leading independent Investment Banking/Stockbroking firms. Danny has managed the IPOs, capital raising and corporate advisory activities for many successful ASX listed companies in the healthcare, technologies and general industrials sectors. He is closely connected to networks of institutional, family office and net worth investors both in Australia and overseas. Danny is currently a Non-Executive Director of Botanix Pharmaceuticals and a member of the Investment Committee for the Baker Heart and Diabetes Institute Foundation.
    Professor Andrew Way Non-Executive Director Apr 2025
    Prof. Way commenced his career as a nurse in the UK National Health Service (NHS) and after a range of clinical positions, moved first into nursing leadership and then into general management. Andrew has held several senior executive roles hospitals in both the UK NHS and Australia. He has been a Chief Executive for nearly 25 years, recently as the CEO of Alfred Health in Melbourne, Victoria, finishing in 2024. Andrew has led several hospitals through major clinical and non-clinical digital transformations. Awarded an AM for his services in support of clinical research and leadership, he continues to advocate for integration of clinical research and clinical practice. Andrew is currently Board Chair of Latrobe Regional Health, Board Chair of HealthShare Victoria, a Director of Australian College of Health Service Management (ACHSM) and a Director of Melbourne Primary Care Network (MPCN). He continues to hold other health related advisory roles.
    Mr Michael Sapountzis Company Secretary Mar 2019
    -
    Matthew Gepp CFO
    -
    Michael Sapountzis Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 185,232,839 13.79%
    Mr Malcolm Pradhan 106,416,160 7.92%
    Mr Raymond Howard Blight 66,964,657 4.98%
    BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient> 49,523,333 3.69%
    Mr Paul John Van Dyk 41,191,171 3.07%
    Citicorp Nominees Pty Limited 40,869,955 3.04%
    Mr Dean Anthony Mackenzie 25,843,400 1.92%
    Rewmicman Pty Ltd <Smallman Family A/C> 25,232,039 1.88%
    Mrs Katrina Elizabeth Doyle 22,793,199 1.70%
    MNMD Pty Ltd <Quirke Super Fund A/C> 20,668,086 1.54%
    Caledonia Nominees Pty Ltd <Caledonia A/C> 19,976,377 1.49%
    UBS Nominees Pty Ltd 18,659,561 1.39%
    Mast Financial Pty Ltd <A To Z Investment A/C> 12,500,000 0.93%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 10,865,922 0.81%
    Merrill Lynch (Australia) Nominees Pty Limited 10,092,199 0.75%
    Aylward Master Pty Ltd <Aylward Family Master A/C> 10,000,000 0.74%
    Gliocas Investments Pty Ltd <Gliocas Growth Fund A/C> 9,380,393 0.70%
    Sandhurst Trustees Ltd <Cyan C3G Fund A/C> 8,553,043 0.64%
    Emerald Shares Pty Limited <Emerald Unit A/C> 7,150,000 0.53%
    Mr Vivek Ramakrishnan and Miss Nisha Srinivasan 7,021,913 0.52%

    Profile

    since

    Note